Zenosense Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
26.80
4.40
1.00
259.60
480.70
Other Current Assets
76.70
-
4.20
9.40
-
Total Current Assets
103.50
4.40
5.20
269.00
480.70
Total Assets
103.50
4.40
5.20
269.00
480.70
ST Debt & Current Portion LT Debt
1.70
20.00
110.00
73.30
284.50
Accounts Payable
19.10
-
-
-
-
Other Current Liabilities
2.60
90.40
151.30
176.90
249.80
Total Current Liabilities
23.30
110.40
261.30
250.20
534.30
Total Liabilities
23.30
110.40
261.30
250.20
534.30
Common Equity (Total)
80.10
105.90
256.10
18.80
53.60
Total Shareholders' Equity
80.10
105.90
256.10
18.80
53.60
Total Equity
80.10
105.90
256.10
18.80
53.60
Liabilities & Shareholders' Equity
103.50
4.40
5.20
269.00
480.70

About Zenosense

View Profile
Address
Avenida Cortes Valencianas 58
Valencia Valencia 46015
Spain
Employees -
Website http://zenosense.net
Updated 07/08/2019
Zenosense, Inc. engages in developing medical devices. It includes the detection of the Methicillin-resistant Staphylococcus aureus. The firm uses Acute Myocardial Infarction, and MIDS Cardiac technologies.